Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.
We're tracking ALTEOGEN Inc.'s market expansion
2 signals in the last 90 days.
How ALTEOGEN Inc.'s international expansion compares to its competitors
ALTEOGEN Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ALTEOGEN Inc.You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
D&D Pharmatech, Alteogen, and Peptron stocks surged as D&D prepares to present MASH pipeline data at EASL conference. Analysts highlight upcoming clinical results and technology transfer deals.
KOSDAQ index fell 2.41% to 1084 amid institutional selling. Biotech stocks like Alteogen, Peptron, and Caregen rose, while robotics stocks plummeted following US semiconductor decline.
KOSPI rose 2.25% to 8228.70 driven by semiconductor stocks, with SK Hynix surging 9.31% and Samsung Electronics up 2.68%, while KOSDAQ fell 3.36% amid polarized market conditions.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about ALTEOGEN Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
